期刊
BMC MEDICAL RESEARCH METHODOLOGY
卷 21, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12874-021-01297-8
关键词
Estrogen receptor; Progesterone receptor; Pathway activities; LASSO; Growth factor
资金
- National Natural Science Foundation of China [82002979]
- Scientific Research and Development Funds of Peking University People's Hospital [RDY2020-16]
- Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation
- Fundamental Research Funds for the Central Universities [BMU2020PYB022, BMU2021PYB013]
The loss of PR expression in ER+/HER2- breast cancers indicates a worse prognosis and insensitivity to anti-estrogen therapy. Various PR expression statuses in these cancers can be indicative of molecular variation, particularly in relation to the activation of growth factor pathways.
Purpose PR loss in ER+/HER2- breast cancer indicates worse prognosis and insensitivity to anti-estrogen therapy, while the mechanisms of PR loss in ER+/HER2- breast cancer remain unrevealed. Methods In this study, ER+/PR+/HER2- and ER+/PR-/HER2- breast cancer cases from TCGA were used. 1387 pathways were analyzed and used as variables for classifying the two groups with LASSO regression. Results ER+/PR+/HER2- and ER+/PR-/HER2- breast cancer groups can be classified by a combination of 13 pathways using their activity score. Among the 13 pathways, those involving growth factors and ion-channel transporters were most significant in the distinction, followed by pathways involving immune modulation and cell metabolism. Two growth factor pathways, EGF and IGF-1, were deferentially regulated in ER+/PR+/HER2- and ER+/PR-/HER2- groups. Conclusions In conclusion, this study indicated in ER+/HER2- breast cancers the various status of PR expression can be an indication of molecular variation, particularly for the growth factor pathway activation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据